Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$4.96 +4.6%	$4.65	$3.61 ▼ $11.09	$55.87M	1.52	84,524 shs	65,715 shs
ENLV Enlivex Therapeutics	$1.05 +1.9%	$1.26	$0.81 ▼ $2.10	$24.36M	0.8	1.30 million shs	887,884 shs
LPTX Leap Therapeutics	$0.30 +8.3%	$0.32	$0.22 ▼ $4.79	$11.40M	-0.27	2.08 million shs	1.03 million shs
TELO Telomir Pharmaceuticals	$1.45 -3.3%	$1.62	$1.12 ▼ $8.40	$48.42M	-0.67	441,320 shs	169,180 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	+4.64%	+5.31%	+0.40%	+8.30%	-49.54%
ENLV Enlivex Therapeutics	+1.94%	-42.31%	-10.26%	+7.69%	-14.63%
LPTX Leap Therapeutics	+8.29%	+11.08%	-16.63%	-18.32%	-89.44%
TELO Telomir Pharmaceuticals	-3.33%	-2.68%	-29.61%	-30.95%	-73.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DTIL Precision BioSciences	4.0691 of 5 stars	3.5	1.0	4.6	2.9	1.7	0.6
ENLV Enlivex Therapeutics	3.3296 of 5 stars	3.7	5.0	0.0	2.9	0.8	0.6
LPTX Leap Therapeutics	2.1924 of 5 stars	3.0	5.0	0.0	0.0	0.0	0.6
TELO Telomir Pharmaceuticals	2.6734 of 5 stars	3.8	2.0	0.0	2.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DTIL Precision BioSciences	3.00	Buy	$47.00	847.58% Upside
ENLV Enlivex Therapeutics	3.33	Buy	$10.00	852.38% Upside
LPTX Leap Therapeutics	2.00	Hold	$3.38	1,033.31% Upside
TELO Telomir Pharmaceuticals	3.50	Strong Buy	$15.00	934.48% Upside

Current Analyst Ratings Breakdown

Latest LPTX, DTIL, TELO, and ENLV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/29/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
7/22/2025	ENLV Enlivex Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DTIL Precision BioSciences	$1.26M	46.36	N/A	N/A	$2.89 per share	1.72
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	$1.00 per share	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	$0.14 per share	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DTIL Precision BioSciences	$7.17M	-$8.81	N/A	N/A	N/A	-6,205.79%	-176.47%	-69.05%	11/3/2025 (Estimated)
ENLV Enlivex Therapeutics	-$15.01M	-$0.66	N/A	N/A	N/A	N/A	-57.67%	-50.52%	8/29/2025 (Estimated)
LPTX Leap Therapeutics	-$67.56M	-$1.58	N/A	N/A	N/A	N/A	-237.65%	-155.38%	N/A
TELO Telomir Pharmaceuticals	-$16.53M	-$0.54	N/A	N/A	N/A	N/A	-4,595.08%	-1,750.91%	11/11/2025 (Estimated)

Latest LPTX, DTIL, TELO, and ENLV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/29/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	LPTX Leap Therapeutics	-$0.29	-$0.40	-$0.11	-$0.40	N/A	N/A
8/14/2025	Q2 2025	TELO Telomir Pharmaceuticals	-$0.08	-$0.17	-$0.09	-$0.17	N/A	N/A
8/7/2025	Q2 2025	DTIL Precision BioSciences	-$0.09	-$2.13	-$2.04	-$2.13	$6.27 million	$0.02 million
5/30/2025	Q1 2025	ENLV Enlivex Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
ENLV Enlivex Therapeutics	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DTIL Precision BioSciences	0.66	5.18	5.18
ENLV Enlivex Therapeutics	N/A	7.20	7.20
LPTX Leap Therapeutics	N/A	1.34	2.41
TELO Telomir Pharmaceuticals	N/A	2.39	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DTIL Precision BioSciences	37.99%
ENLV Enlivex Therapeutics	1.02%
LPTX Leap Therapeutics	30.46%
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
DTIL Precision BioSciences	4.50%
ENLV Enlivex Therapeutics	12.28%
LPTX Leap Therapeutics	7.50%
TELO Telomir Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DTIL Precision BioSciences	200	11.79 million	11.26 million	No Data
ENLV Enlivex Therapeutics	70	23.65 million	20.75 million	Optionable
LPTX Leap Therapeutics	40	41.44 million	38.33 million	Optionable
TELO Telomir Pharmaceuticals	1	32.28 million	N/A	N/A

LPTX, DTIL, TELO, and ENLV Headlines

Recent News About These Companies

TELO Makes Progress Toward Human Trials

August 15, 2025 | msn.com

Telomir-1 inhibits key histone demethylase enzymes in vitro

August 12, 2025 | bioworld.comB

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic ...

August 8, 2025 | kansascity.comK

Telomir Flat on Trial Data Release

August 7, 2025 | baystreet.ca

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction

August 7, 2025 | accessnewswire.comA

Telomir Pharmaceuticals (TELO) Expected to Announce Earnings on Tuesday

August 6, 2025 | marketbeat.com

Telomir Pharmaceuticals Announces Promising Preclinical Results

July 26, 2025 | theglobeandmail.com

Telomir Pharmaceuticals stock surges on promising Progeria treatment results

July 25, 2025 | investing.com

TELO Announces Another Important Breakthrough

July 25, 2025 | finance.yahoo.com

Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's

July 24, 2025 | accessnewswire.comA

Telomir Pharmaceuticals (NASDAQ:TELO) Trading Down 5% - Here's What Happened

July 23, 2025 | marketbeat.com

Telomir Pharmaceuticals Skyrockets 150% on Breakthrough Preclinical Cancer Results

July 18, 2025 | msn.com

Telomir Pharmaceuticals stock soars after promising cancer treatment data

July 18, 2025 | investing.com

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains

July 18, 2025 | msn.com

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

July 18, 2025 | accessnewswire.comA

Telomir says data show Telomir-1 reversed epigenetic silencing

July 17, 2025 | msn.com

Telomir Pharmaceuticals Reveals Promising Preclinical Cancer Results

July 17, 2025 | tipranks.com

Telomir Pharmaceuticals Inc News (TELO) - Investing.com

July 1, 2025 | investing.com

Telomir Pharmaceuticals Reports Positive Preclinical Data

June 18, 2025 | tipranks.com

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

June 18, 2025 | accessnewswire.comA

Telomir Pharma’s Telomir-1 shows dose-dependent restoration of neurological, liver & kidney functions in preclinical for Wilson’s disease

June 14, 2025 | pharmabiz.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPTX, DTIL, TELO, and ENLV Company Descriptions

Precision BioSciences NASDAQ:DTIL

$4.96 +0.22 (+4.64%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.94 -0.01 (-0.30%)

As of 08/22/2025 06:31 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Enlivex Therapeutics NASDAQ:ENLV

$1.05 +0.02 (+1.94%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.03 -0.02 (-1.43%)

As of 08/22/2025 07:57 PM Eastern

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Leap Therapeutics NASDAQ:LPTX

$0.30 +0.02 (+8.29%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.30 0.00 (-0.94%)

As of 08/22/2025 07:59 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Telomir Pharmaceuticals NASDAQ:TELO

$1.45 -0.05 (-3.33%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.46 +0.01 (+0.69%)

As of 08/22/2025 07:58 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time